W. R. Berkley
WRB
$69.99
-0.16%
W.R. Berkley Corporation is an insurance holding company that operates through a network of subsidiaries, primarily underwriting commercial casualty insurance with a focus on niche products such as excess and surplus lines, workers' compensation, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses. The company is a specialist in the property and casualty insurance industry, distinguished by its decentralized operating model and expertise in underwriting complex, hard-to-place risks that often fall outside standard carrier appetites. Currently, investor attention centers on the company's ability to sustain underwriting profitability amid a softening premium rate environment, with recent quarterly results showing modest revenue growth and stable net income. The broader narrative includes debates over reserve adequacy, investment income tailwinds from higher interest rates, and the potential for margin compression as competition intensifies in the E&S market.…
WRB
W. R. Berkley
$69.99
Related headlines
Investment Opinion: Should I buy WRB Today?
The synthesized recommendation is Hold. WRB's strong fundamentals, including an 18.34% ROE and a conservative balance sheet, are offset by decelerating revenue growth of 3.98% and a neutral analyst consensus with an average target price of $69.41, implying a slight downside from the current price of $69.99. The core thesis is that WRB is a well-managed, defensive insurer but lacks near-term catalysts to drive significant outperformance.
Supporting evidence includes a trailing PE of 15.65x, which is a 5-10% discount to the industry average of 16-18x, and a price-to-sales ratio of 1.89x, which is relatively low. The company generates robust free cash flow of $3.37 billion (TTM) and has a dividend yield of 2.52% with a sustainable payout ratio of 39.35%. However, revenue growth has slowed to 3.98% year-over-year, and the PEG ratio of 7.63 suggests the market is pricing in higher growth than is currently materializing.
The biggest risks that could invalidate the thesis include a continued deceleration in revenue growth, adverse reserve development, and increased competition in the E&S market. The rating would upgrade to Buy if revenue growth reaccelerates above 5% and the forward PE compresses below 14x, or downgrade to Sell if revenue growth turns negative or if reserve charges emerge. Relative to its history and peers, WRB appears fairly valued, with the price-to-book ratio of 2.87x above the historical average of 2.5x, suggesting limited margin of safety.
Sign up to view all
WRB 12-Month Price Forecast
WRB presents a balanced risk-reward profile. The company's strong ROE, low leverage, and robust free cash flow provide downside protection, but decelerating revenue growth and a neutral analyst consensus limit upside potential. The stock's low beta makes it a defensive holding, but it has underperformed the market over the past year. I would upgrade to bullish if revenue growth reaccelerates above 5% and the forward PE remains below 15x, or downgrade to bearish if revenue growth turns negative or reserve charges emerge. The current stance is neutral, with a slight preference for the base case given stable profitability and cash generation.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on W. R. Berkley's 12-month outlook, with a consensus price target around $69.41 and implied upside of -0.8% versus the current price.
Average Target
$69.41
0 analysts
Implied Upside
-0.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$51 - $83
Analyst target range
WRB is covered by 17 analysts, with a consensus recommendation of 'Hold' (average rating 3.39 on a scale where 1 is Strong Buy and 5 is Strong Sell). The average target price is $69.41, which implies a slight downside of 0.8% from the current price of $69.99. The consensus leans neutral to slightly bearish, with no strong buy ratings and a mix of hold and underperform recommendations. Recent institutional ratings show a predominantly cautious stance: Evercore ISI and Wells Fargo maintain Underperform/Underweight ratings, while Goldman Sachs upgraded to Buy in June 2026, providing a lone bullish voice. The target price range spans from a low of $51.00 to a high of $83.00, a wide spread of 62.7% that signals significant uncertainty about the company's future performance. The high target of $83.00 likely assumes multiple expansion, accelerating premium growth, and continued reserve strength, while the low target of $51.00 prices in margin compression, adverse reserve development, or a broader industry downturn. The dispersion of targets and the lack of consensus direction suggest that analysts are divided on the outlook, with some seeing value and others concerned about headwinds. Given the low short ratio of 0.04, there is little short-selling pressure, but the neutral consensus and recent downgrades indicate that positive catalysts are needed to shift sentiment.
Bulls vs Bears: WRB Investment Factors
The bear case currently has stronger evidence due to decelerating revenue growth, a neutral analyst consensus with a target price below the current price, and significant underperformance versus the broader market. However, the bull case is supported by WRB's strong ROE of 18.34%, robust free cash flow of $3.37 billion, and a conservative balance sheet with a debt-to-equity ratio of 0.293. The most critical tension is whether the company can sustain its underwriting profitability and return on equity as premium rates soften and competition intensifies in the E&S market. If WRB can maintain its niche underwriting discipline and continue to generate strong cash flows, the stock could re-rate; otherwise, further multiple compression is likely.
Bullish
- Strong ROE and conservative balance sheet: WRB generates an 18.34% return on equity (TTM), well above the industry average, while maintaining a debt-to-equity ratio of just 0.293 and interest coverage of 19.43x. This combination of high profitability and low leverage provides a durable competitive advantage and ample financial flexibility.
- Robust free cash flow and shareholder returns: The company generated $3.37 billion in free cash flow (TTM) and $667.9 million in operating cash flow in Q1 2026, easily covering $33.7 million in dividends and $302.4 million in share repurchases. The 2.52% dividend yield is supported by a conservative 39.35% payout ratio, leaving room for continued capital returns.
- Improving profitability and margin expansion: Q1 2026 net margin rose to 13.97% from 11.77% a year earlier, while operating margin reached 16.70%. Gross margin also improved significantly to 47.51% from 22.13% in Q1 2025, though this metric can be volatile due to insurance accounting.
- Attractive valuation relative to peers and history: WRB trades at a trailing PE of 15.65x and forward PE of 14.46x, a 5-10% discount to the P&C insurance sector average of 16-18x. The price-to-sales ratio of 1.89x is also low, suggesting the stock is not expensive on a revenue basis.
Bearish
- Decelerating revenue growth: Revenue grew only 3.98% year-over-year in Q1 2026 to $3.689 billion, a sharp deceleration from prior periods. This slowdown reflects a maturing insurance cycle and intensifying competition in the E&S market, which could pressure future growth.
- Analyst consensus is neutral with downside risk: The average analyst target price of $69.41 implies a slight downside of 0.8% from the current price of $69.99. With a consensus rating of 'Hold' (3.39 on a 1-5 scale) and recent Underperform ratings from Evercore ISI and Wells Fargo, sentiment is cautious.
- Elevated PEG ratio signals growth concerns: The PEG ratio of 7.63 is unusually high, indicating that the market is paying a significant premium for expected earnings growth. This could lead to multiple compression if growth fails to accelerate.
- Price-to-book above historical average: The price-to-book ratio of 2.87x is above the historical average of around 2.5x, suggesting limited margin of safety. If earnings disappoint, the stock could revert to its historical valuation, implying downside.
WRB Technical Analysis
WRB is in a recovery phase within a broader range-bound consolidation. The stock has declined 4.25% over the past year, significantly underperforming the S&P 500's 15.01% gain, yet it trades at 69.99, which is 48.5% of its 52-week range (low of 62.87, high of 78.96). This positioning suggests the stock is neither overextended nor deeply undervalued, but rather in the middle of its annual range, reflecting a market that is cautiously re-evaluating the name after a period of weakness. The 1-month change of +0.55% and 3-month change of +4.18% indicate improving short-term momentum, diverging from the negative 1-year trend. This divergence could signal a trend reversal or mean reversion, especially as the 1-month relative strength versus SPY is +1.51%, outperforming the market's -0.96% decline. The 6-month change of +6.46% further supports a gradual recovery, though the stock remains below its 52-week high, suggesting that momentum is still fragile and could be tested by resistance. Key technical levels are defined by the 52-week low at 62.87 (support) and the 52-week high at 78.96 (resistance). A breakout above 78.96 would signal a renewed uptrend and potentially attract momentum buyers, while a breakdown below 62.87 could trigger further selling and test longer-term support. The stock's beta of 0.283 indicates very low volatility relative to the market—roughly 72% less volatile than SPY—which makes it a defensive holding but also limits upside participation in broad rallies. The maximum drawdown of -19.02% over the past year highlights the stock's vulnerability during periods of sector-specific stress, despite its low beta.
Beta
0.28
0.28x market volatility
Max Drawdown
-19.0%
Largest decline past year
52-Week Range
$63-$79
Price range past year
Annual Return
-4.3%
Cumulative gain past year
| Period | WRB Return | S&P 500 |
|---|---|---|
| 1m | +0.5% | -0.5% |
| 3m | +4.2% | +2.3% |
| 6m | +6.5% | +16.6% |
| 1y | -4.3% | +14.8% |
| ytd | +0.9% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WRB Fundamental Analysis
WRB's revenue trajectory shows modest growth, with the most recent quarter (Q1 2026) reporting revenue of $3.689 billion, up 3.98% year-over-year from $3.547 billion in Q1 2025. Sequentially, revenue declined slightly from $3.719 billion in Q4 2025, but the multi-quarter trend reveals a steady increase from $3.310 billion in Q2 2024 to the current level, indicating a consistent, albeit decelerating, growth path. The domestic insurance segment dominates, contributing $3.044 billion (82.5% of total revenue), while the global reinsurance segment adds $455 million (12.3%), highlighting the company's reliance on its core U.S. commercial lines. This growth is primarily driven by niche underwriting and favorable rate conditions, but the deceleration from double-digit growth in prior years to low single digits suggests a maturing cycle and potential headwinds from increased competition. Profitability remains solid, with Q1 2026 net income of $515.2 million and a net margin of 13.97%, up from 11.77% in Q1 2025. The gross margin for Q1 2026 was 47.51%, a significant improvement from 22.13% in the prior-year quarter, though this metric can be volatile due to insurance accounting. Operating margin stood at 16.70%, and the company maintains a strong return on equity of 18.34% (TTM), indicating efficient capital deployment. However, the net margin has fluctuated, and the Q4 2025 net margin of 12.09% was lower than Q1 2026, suggesting some quarterly variability. The balance sheet is conservatively managed, with a debt-to-equity ratio of 0.293, well below the industry average, and a current ratio of 1.39, indicating adequate liquidity. Free cash flow (TTM) is robust at $3.37 billion, providing ample internal funding for growth and shareholder returns. The company generated $667.9 million in operating cash flow in Q1 2026, covering dividends of $33.7 million and share repurchases of $302.4 million, demonstrating strong cash generation. The dividend yield of 2.52% and payout ratio of 39.35% suggest a sustainable dividend policy, while the low debt level and high interest coverage (19.43x) underscore financial stability.
Quarterly Revenue
$3.7B
2026-03
Revenue YoY Growth
+4.0%
YoY Comparison
Gross Margin
47.5%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WRB Overvalued?
Since WRB is profitable with positive net income, the PE ratio is the primary valuation metric. The trailing PE is 15.65x, while the forward PE is 14.46x, implying an 8.2% earnings growth expectation embedded in the forward multiple. This modest gap suggests the market anticipates steady but not explosive earnings growth, consistent with the company's mature, low-beta profile. The PEG ratio of 7.63, however, appears elevated and may reflect temporary earnings distortions or a mismatch between the PE and growth rate, warranting caution. Compared to the property and casualty insurance industry, WRB's trailing PE of 15.65x is slightly below the sector average of approximately 16-18x, representing a modest discount of roughly 5-10%. The price-to-book ratio of 2.87x is also in line with peers, while the price-to-sales ratio of 1.89x is relatively low, suggesting the stock is not expensive on a revenue basis. The discount may be justified by the company's lower growth trajectory and exposure to commercial lines, but its strong ROE and conservative balance sheet could argue for a premium over time. Historically, WRB's PE ratio has ranged from a low of 7.8x in Q1 2022 to a high of 26.5x in Q2 2022, with the current 15.65x sitting near the middle of that range. The price-to-book ratio of 2.87x is above the historical average of around 2.5x, indicating that the market is pricing in a higher valuation relative to book value than in the past. This could reflect improved profitability and lower risk, but also suggests limited margin of safety if earnings disappoint.
PE
15.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 10x~18x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.9x
Enterprise Value Multiple
Investment Risk Disclosure
WRB faces financial and operational risks primarily from its reliance on the domestic insurance segment, which contributed 82.5% of total revenue in Q1 2026. A downturn in commercial lines or adverse reserve development could significantly impact earnings, as evidenced by the quarterly net margin volatility, which ranged from 12.09% in Q4 2025 to 13.97% in Q1 2026. Additionally, the company's growth has decelerated to 3.98% year-over-year, and any further slowdown could pressure profitability. The debt-to-equity ratio of 0.293 is low, but the company's exposure to catastrophic events and long-tail liabilities inherent in casualty insurance remains a persistent risk.
Market and competitive risks include valuation compression if WRB fails to meet growth expectations. The stock trades at a forward PE of 14.46x, which is a slight discount to peers, but the PEG ratio of 7.63 suggests the market may be overpaying for growth. The low beta of 0.283 indicates low correlation with the broader market, but this also limits upside during rallies. Recent news highlights Palomar's high-risk insurance strategy paying off, indicating that competitors are gaining traction in niche markets, which could erode WRB's market share. Furthermore, the E&S market is becoming more competitive, potentially leading to pricing pressure and margin erosion.
In a worst-case scenario, a combination of accelerating premium rate declines, adverse reserve development, and a broad market downturn could drive WRB's stock down to its 52-week low of $62.87, representing a decline of approximately 10.2% from the current price of $69.99. If analyst bear-case targets are met, the stock could fall to $51.00, a 27.1% decline. The maximum drawdown over the past year was -19.02%, indicating that such a decline is plausible during periods of sector-specific stress. Investors could lose 10-27% of their investment in this adverse scenario.
FAQ
The key risks include financial, competitive, macro, and company-specific factors. Financially, WRB's revenue growth has decelerated to 3.98% year-over-year, and any further slowdown could pressure profitability. Competitively, the E&S market is becoming more crowded, as evidenced by Palomar's high-risk strategy paying off, which could erode WRB's market share. Macro risks include a low beta of 0.283, which limits upside during market rallies, and potential interest rate changes affecting investment income. Company-specific risks include adverse reserve development, which could lead to charges and reduce earnings. Ranked by severity, the most significant risk is a sustained decline in premium rates, followed by reserve inadequacy and competitive pressures.
The 12-month forecast for WRB includes three scenarios. The base case (55% probability) targets a range of $65 to $72, assuming revenue growth of 3-4% and stable margins. The bull case (25% probability) targets $78.96 to $83, driven by premium rate increases and multiple expansion. The bear case (20% probability) targets $51 to $62.87, reflecting margin compression and adverse reserve development. The most likely scenario is the base case, with the key assumption that WRB maintains its underwriting discipline and generates consistent free cash flow. However, the wide analyst target range of $51 to $83 highlights significant uncertainty.
WRB appears fairly valued to slightly undervalued relative to its peers. The trailing PE of 15.65x and forward PE of 14.46x are below the P&C insurance industry average of 16-18x, representing a 5-10% discount. However, the price-to-book ratio of 2.87x is above the historical average of 2.5x, suggesting limited margin of safety. The PEG ratio of 7.63 is elevated, indicating that the market may be pricing in higher growth than is currently materializing. Overall, the valuation implies that the market expects steady but not explosive earnings growth, consistent with WRB's mature, low-beta profile.
WRB may be a good buy for conservative, income-oriented investors seeking low volatility and a sustainable dividend, but it is not without risks. The stock trades at $69.99, with an average analyst target of $69.41, implying a slight downside of 0.8%. The company's strong ROE of 18.34% and robust free cash flow of $3.37 billion support its financial health, but revenue growth has slowed to 3.98% year-over-year. The biggest downside risk is a continued deceleration in premium growth or adverse reserve development, which could push the stock toward its 52-week low of $62.87. For those willing to accept modest growth in exchange for stability, WRB could be a suitable holding, but it may not appeal to investors seeking high growth.
WRB is more suitable for long-term investment, given its low beta of 0.283, stable dividend yield of 2.52%, and consistent free cash flow generation. The company's earnings visibility is moderate, with a mature business model and a history of profitability. Short-term trading is less attractive due to low volatility and the lack of near-term catalysts, as reflected in the neutral analyst consensus. A suggested minimum holding period is 2-3 years to allow for potential re-rating and to benefit from dividend compounding. Investors should monitor quarterly earnings for signs of growth acceleration or margin deterioration.